IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

December 3, 2022

Study Completion Date

August 25, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

Biological: IBI322

Recombinant anti-human CD47/PD-L1 bispecific antibody injection

Trial Locations (1)

Shandong Province Cancer Hospital, Jinan

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04912466 - IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. | Biotech Hunter | Biotech Hunter